GPCR Inhibition With ICB May Be Needed to Reactivate Antitumor Immune Response

Newswise — In a new study published in Nature Immunology, researchers at University of California San Diego School of Medicine, led by Silvio Gutkind, PhD, use a computational and synthetic biology approach to show that a GPCR checkpoint drives T cell dysfunction and immunotherapy failure. The findings may inform new treatment strategies and improve upon existing immune checkpoint blockade (ICB) therapies.